A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive function.

This study investigated the effects of omega-3 supplementation on various aspects of cognitive function in adults. The researchers specifically looked at how different doses of omega-3, including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) either alone or in combination, influenced mental abilities.

The intervention was oral supplementation with omega-3 fatty acids. The comparators were control groups, which typically received a placebo or no active intervention.

The outcome measures were a wide range of cognitive functions, categorized into:

• Attention: The ability to focus and sustain concentration.
• Perceptual speed: How quickly one can process visual information and react.
• Language: Abilities related to comprehension and production of language.
• Primary memory: Often referred to as short-term memory or working memory, the ability to hold and manipulate information for a brief period.
• Visuospatial functions: The ability to understand and interpret visual information and spatial relationships.
• Global cognitive abilities: An overall measure of general mental function, often encompassing multiple cognitive domains.
• Episodic memory: The ability to recall specific events and experiences from the past.

The study also performed a dose-response analysis, which means they specifically examined how changes in the amount of omega-3 consumed related to changes in these cognitive outcomes. This allowed them to estimate the effect of increasing omega-3 intake by a specific amount (2000 mg/day) on each cognitive domain.

This systematic review and meta-analysis synthesized data from 58 individual randomized controlled trials (RCTs).

The population included a broad range of adults, specifically those aged 18 years and older. The participants' cognitive health status varied significantly across the included studies:

• 32 studies enrolled cognitively healthy individuals.
• 16 studies included participants with cognitive impairments (mild to moderate).
• 3 studies focused specifically on individuals with Alzheimer's disease (AD).
• 3 studies included participants with both AD and other cognitive impairments.
• 2 trials involved participants with general memory issues.
• 2 trials assessed participants with other mental disorders.

This diverse participant pool means the findings are potentially applicable to a wide range of individuals, from those looking to enhance normal cognitive function to those with existing cognitive challenges.

The setting for these studies was global, with trials conducted in:

• USA and Canada (14 studies)
• Europe (20 studies)
• Asia/Oceania (24 studies)

The intervention duration across the 58 studies was highly variable, ranging from a short 4 weeks to a very long 160 weeks (approximately 3 years). The daily dosage of omega-3 supplementation also varied widely, from 230 mg/day to 4950 mg/day.

Some studies (9 out of 58) used multi-component interventions, combining omega-3 with other compounds like vitamins or antioxidants. This means that for these specific studies, the observed effects might not be solely attributable to omega-3.

The original studies included in this meta-analysis used a variety of standardized instruments and scales to assess cognitive function. Because different studies used different tests, the meta-analysis employed a statistical technique called Standardized Mean Difference (SMD) to combine and compare results across these diverse measures. An SMD allows researchers to express the effect of an intervention in terms of standard deviation units, making it possible to compare outcomes measured on different scales.

Common cognitive assessment tools identified in the included studies were:

• Mini-Mental State Examination (MMSE): This is a widely used screening tool for global cognitive abilities, assessing orientation, attention, memory, language, and visuospatial skills. Scores typically range from 0 to 30, with higher scores indicating better cognitive function. It was used in 19 studies for global cognition.
• Trail Making A and B and Stroop Tests: These tests are commonly used to assess attention, executive function (such as planning and problem-solving), and processing speed. They were used in 17 studies.
• Block Design: This test, often part of larger intelligence batteries, measures visuospatial functions and problem-solving abilities. It was used in 4 studies.
• Various recall assessment tools: A range of different tests designed to measure memory, particularly primary (short-term) and episodic memory, were used in 4 studies.

For the purpose of the meta-analysis, the researchers extracted the means and standard deviations (SDs) of changes in these cognitive outcomes from baseline for both the intervention and control groups. If mean changes were not directly available, they were calculated. When necessary, results were standardized to identical units, and numerical estimates presented in graphical formats were extracted using specialized software (Plot Digitizer). This meticulous approach ensured that data from different studies, despite using varied measurement tools, could be meaningfully combined and analyzed.

This study is a systematic review and dose-response meta-analysis of Randomized Controlled Trials (RCTs). This design is considered one of the highest levels of evidence in medical research because it systematically synthesizes findings from multiple high-quality studies, providing a more robust estimate of an intervention's effect than any single study alone.

How they ran the study:

1. Systematic Search: The researchers conducted a comprehensive search of major scientific databases (PubMed, Scopus, and ISI Web of Science) from their inception up to December 2024.